Literature DB >> 2558065

Expression of desmin and myoglobin in rhabdomyosarcomas and in developing skeletal muscle.

R L Carter1, K P McCarthy, L G Machin, C F Jameson, E R Philp, C R Pinkerton.   

Abstract

Immunohistochemical staining for desmin and myoglobin was investigated in 35 rhabdomyosarcomas from young people and in skeletal muscle from 16 human fetuses of known gestational age. Twenty-nine of the rhabdomyosarcomas expressed desmin but six undifferentiated or poorly-differentiated tumours were desmin negative. Of the desmin positive cases, most undifferentiated or poorly-differentiated sarcomas expressed desmin alone (12/35). Tumours with increasing rhabdomyoblastomic differentiation co-expressed myoglobin (9/35) and well-differentiated examples also contained cross-striations (7/35). Skeletal muscle from fetuses aged 8 weeks or less consisted mainly of primitive desmin negative round cells. As the cells began to differentiate they quickly expressed desmin and, at approximately 10 weeks, myoglobin was expressed and cross-striations were seen. The combined results strengthen the view that desmin (within a strictly defined context of round cell tumours in young people) is a reliable marker for rhabdomyoblastic differentiation. Support is also given to the notion that very primitive rhabdomyosarcomas may be desmin-negative, although the difficulties of establishing firm diagnoses for some of these tumours is emphasized.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2558065     DOI: 10.1111/j.1365-2559.1989.tb01624.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

1.  The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors.

Authors:  S Gattenloehner; A Vincent; I Leuschner; S Tzartos; H K Müller-Hermelink; T Kirchner; A Marx
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

2.  HTS-Compatible Patient-Derived Cell-Based Assay to Identify Small Molecule Modulators of Aberrant Splicing in Myotonic Dystrophy Type 1.

Authors:  Debra A O'Leary; Leonardo Vargas; Orzala Sharif; Michael E Garcia; Yury J Sigal; Siu-Kei Chow; Christian Schmedt; Jeremy S Caldwell; Achim Brinker; Ingo H Engels
Journal:  Curr Chem Genomics       Date:  2010-03-19

3.  GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells.

Authors:  J A Marchal; J Prados; C Melguizo; J A Gómez; J Campos; M A Gallo; A Espinosa; N Arena; A Aránega
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

4.  Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation.

Authors:  Karin Schilbach; Mohammed Alkhaled; Christian Welker; Franziska Eckert; Gregor Blank; Hendrik Ziegler; Marco Sterk; Friederike Müller; Katja Sonntag; Thomas Wieder; Heidi Braumüller; Julia Schmitt; Matthias Eyrich; Sabine Schleicher; Christian Seitz; Annika Erbacher; Bernd J Pichler; Hartmut Müller; Robert Tighe; Annick Lim; Stephen D Gillies; Wolfgang Strittmatter; Martin Röcken; Rupert Handgretinger
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

5.  Evaluation of Myogenin and MyoD1 as Immunohistochemical Markers of Canine Rhabdomyosarcoma.

Authors:  Joanne L Tuohy; Brittney J Byer; Suzanne Royer; Charles Keller; Margaret A Nagai-Singer; Daniel P Regan; Bernard Seguin
Journal:  Vet Pathol       Date:  2021-03-11       Impact factor: 2.221

6.  The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation.

Authors:  K Miekus; E Lukasiewicz; D Jarocha; M Sekula; G Drabik; M Majka
Journal:  Cell Death Dis       Date:  2013-01-17       Impact factor: 8.469

7.  Expression of members of the myf gene family in human rhabdomyosarcomas.

Authors:  J Clark; P J Rocques; T Braun; E Bober; H H Arnold; C Fisher; C Fletcher; K Brown; B A Gusterson; R L Carter
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.